A study on whether a natural sulforaphane supplement can boost glutathione levels
| ISRCTN | ISRCTN15242244 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN15242244 |
| Secondary identifying numbers | SB1 |
- Submission date
- 21/02/2025
- Registration date
- 24/02/2025
- Last edited
- 19/06/2025
- Recruitment status
- Suspended
- Overall study status
- Ongoing
- Condition category
- Other
Plain English summary of protocol
Background and study aims
Glutathione is an important antioxidant that helps protect cells from damage and supports overall health. This study aims to investigate whether taking a supplement containing glucoraphanin and myrosinase can increase glutathione levels in middle-aged adults.
Who can participate?
Healthy adults aged 40 to 65 years who do not smoke, drink excessively, or take antioxidant supplements. Participants must not have any major health conditions that affect glutathione levels.
What does the study involve?
Participants will be randomly assigned to take either a glucoraphanin and myrosinase supplement or a placebo every day for 30 days. Blood samples will be taken before and after the trial to measure glutathione levels. The study is double-blind, meaning neither participants nor researchers will know who is receiving the supplement or placebo.
What are the possible benefits and risks of participating?
There is no guaranteed benefit but participants may experience increased glutathione levels, which could support antioxidant function. The supplement is naturally derived from broccoli. Risks are minimal, but some participants may experience mild digestive discomfort.
Where is the study run from?
DoNotAge.org (UK)
When is the study starting and how long is it expected to run for?
February 2025 to October 2025
Who is funding the study?
DoNotAge.org (UK)
Who is the main contact?
Alan Graves, alan.graves@donotage.org
Contact information
Public
Unit 4 Melbourne Court
Derby
DE24 8LZ
United Kingdom
| Phone | +44 (0)1332691512 |
|---|---|
| hello@donotage.org |
Scientific, Principal Investigator
Unit 4 Melbourne Court
Derby
DE24 8LZ
United Kingdom
| Phone | +44 (0)7575115464 |
|---|---|
| alan.graves@donotage.org |
Study information
| Study design | Single-centre interventional double-blinded randomized placebo-controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Home |
| Study type | Treatment |
| Scientific title | Evaluating the impact of a glucoraphanin and myrosinase supplement on glutathione levels: a randomized, placebo-controlled trial |
| Study objectives | Supplementation with a sulforaphane-boosting product for 30 days will increase blood glutathione levels in middle-aged adults compared to a placebo. |
| Ethics approval(s) | Ethics approval not required |
| Ethics approval additional information | Ethics approval not required, confirmed by the Medical Research Council and NHS Health Research Authority |
| Health condition(s) or problem(s) studied | Effects of glucoraphanin and myrosinase supplementation on glutathione levels in middle-aged adults |
| Intervention | This study is a randomized, double-blind, placebo-controlled trial investigating the effects of glucoraphanin and myrosinase supplementation on glutathione levels in middle-aged adults. Participants will be randomly assigned (1:1) using computer-generated randomisation to receive either a daily dose of 460 mg (two capsules) of glucoraphanin and myrosinase supplementation (SulforaBoost®) or a placebo for 30 days. Blood samples will be collected at baseline and after 30 days to measure glutathione levels. The intervention will be administered orally, and compliance will be monitored through participant self-reporting and supplement count. The study aims to determine whether glucoraphanin and myrosinase supplementation significantly increases glutathione levels compared to placebo. |
| Intervention type | Supplement |
| Primary outcome measure | Glutathione levels measured using blood analysis at baseline (Day 0) and after 30 days of supplementation |
| Secondary outcome measures | There are no secondary outcome measures |
| Overall study start date | 01/02/2025 |
| Completion date | 31/10/2025 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Lower age limit | 40 Years |
| Upper age limit | 65 Years |
| Sex | Both |
| Target number of participants | 20 |
| Key inclusion criteria | Aged 40-65 years |
| Key exclusion criteria | 1. Individuals younger than 40 or older than 65 years 2. Current use of glucoraphanin, myrosinase, or sulforaphane-containing supplements 3. Diagnosed metabolic or chronic diseases affecting glutathione levels (e.g., diabetes, liver disease) 4. Use of antioxidant supplements (e.g., NAC, glutathione, vitamin C, or E) within the past 30 days 5. Smoking or excessive alcohol consumption (>14 units per week) 6. Known allergies to cruciferous vegetables or supplement ingredients 7. Participation in another clinical trial within the past 3 months 8. Pregnancy or breastfeeding |
| Date of first enrolment | 01/03/2025 |
| Date of final enrolment | 30/06/2025 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
United Kingdom
Sponsor information
Research organisation
Unit 4 Melbourne Court
Derby
DE24 8LZ
England
United Kingdom
| Phone | N/A |
|---|---|
| hello@donotage.org | |
| Website | https://www.donotage.org |
Funders
Funder type
Research organisation
No information available
Results and Publications
| Intention to publish date | 01/11/2025 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | The results of this study will be analyzed and submitted for publication in a peer-reviewed scientific journal. Findings may also be shared through conferences, public health discussions, and DoNotAge.org’s communication channels to ensure accessibility to both the scientific community and the public. |
| IPD sharing plan | The datasets generated and analyzed during the current study will be available upon request from Alan Graves (alan.graves@donotage.org). Data will include anonymized participant-level information on glutathione levels before and after supplementation. The data will become available after publication and will be shared with researchers upon request, subject to ethical and legal considerations. Consent for data sharing will be obtained from participants, and all shared data will be fully anonymized. The dataset will not contain any personally identifiable information. |
Editorial Notes
19/06/2025: A temporary suspension of recruitment was enacted due to staffing.
03/04/2025: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/04/2025 to 30/06/2025.
2. The overall end date was changed from 31/08/2025 to 31/10/2025.
3. The plain English summary was updated to reflect these changes.
24/02/2025: Study's existence confirmed by DoNotAge.org.
